


Vaccines and Diagnostics for the Ehrlichioses

Ehrlichia are tick-borne pathogens that cause diseases in livestock and companion animals and emerging life-threatening zoonoses in humans. There is a need for rapid, sensitive and specific immunodiagnostics and effective vaccines for the veterinary and human ehrlichioses. Clayton investigators, Jere W. McBride, Ph.D. and David H. Walker, M.D. and their laboratories at the University of Texas Medical Branch in Galveston, are using molecular strategies to lead the way in vaccine and diagnostic development for *Ehrlichia canis*, a highly prevalent disease in dogs, and *Ehrlichia chaffeensis*, the cause of human monocytotropic ehrlichiosis. They have molecularly identified and characterized novel major immunoreactive proteins of *E. canis* and *E. chaffeensis*, which are considered to be excellent candidates for immunodiagnostic and vaccine development.

Ehrlichioses is an emerging life-threatening human disease that can be fatal if not accurately diagnosed early and treated appropriately. Sensitive and specific **immunodiagnostics for human monocytotropic ehrlichiosis** are needed.

Sensitive and specific **veterinary diagnostics for *E. canis*** based on our antigens are currently in development with commercial partners. Several other patented antigens are available for exclusive or non-exclusive licensing.

Vaccination is the most cost effective means of controlling **veterinary and human ehrlichioses**. Recent research progress has greatly improved the prospects for developing effective vaccines. We are seeking a commercial partner to collaborate with us and our investigators to accelerate the development of a vaccine based on our IP on immunoprotective antigens and our extensive knowledge of the disease.



Intellectual
Property

Through our entity, Research Development Foundation, we have a portfolio of US and international patents and applications, including but not limited to the following: US7432081, US11/684832, US7204992, EP1581638, US11/066648, US6015691, US 11/917390

Available for licensing or partnering

For more information, please contact our business development unit:

Dr. Alexandra Richardson +41-76-342-7147 - arichardson@claytonbiotech.com